Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase 3 Study Evaluating the Prognostic Usefulness of I-123 mIBG Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event

NCT00126438 is registered in ClinicalTrials.gov with GE Healthcare as lead sponsor.

NCT NCT00126438
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00126438 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase 3 Study Evaluating the Prognostic Usefulness of I-123 mIBG Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event
Lead sponsor
GE Healthcare
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2005
Completion date
September 30, 2008
Enrollment
515 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure, congestive